Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

SymBio Pharmaceuticals

Request full access

SymBio Pharmaceuticals aims to develop drugs for patients overlooked by the industry, ensuring vital treatments reach those in need

Tokyo, JapanFounded 2005Biotech & Life Sciences

About SymBio Pharmaceuticals

SymBio Pharmaceuticals is a Japanese pharmaceutical company focused on the development and commercialization of drugs for oncology, hematology, and autoimmune diseases. The company acquires promising drug candidates from a global network of biopharmaceutical companies and academic institutions, focusing on treatments with a high unmet medical need, even in smaller markets. SymBio's business model centers on in-licensing drug candidates that have already shown proof-of-concept in humans, thereby reducing the risk and time associated with early-stage drug discovery. The company then manages the clinical development, regulatory approval, and commercialization of these drugs, primarily in Japan and other Asian markets. Its revenue is generated through the sale of its approved pharmaceutical products. SymBio's client base consists of healthcare providers, hospitals, and pharmacies that treat patients with rare and difficult-to-treat diseases.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2005
Headquarters
Tokyo, Japan
Listing
IPO 2011
Sector
Biotech & Life Sciences

SymBio Pharmaceuticals in the Tokyo ecosystem

Live from Dealroom

The SymBio Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

12 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • DBJ Capital

Series A9 investors entered at this stage

  • Daiichi Sankyo
  • SBI Investment
  • Waseda University
  • VALUE CREATION
  • Japan Asia Investment
  • TNP
  • Mitsubishi UFJ Capital
  • Mizuho Capital
  • Tokyo Small and Medium Business Investment & Consultation

Series B and later2 investors entered at this stage

  • Cephalon
  • Whiz Partners
Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇯🇵 Japan95.2%
🇺🇸 United States4.8%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about SymBio Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See SymBio Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.